Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04505813Phase 1Suspended

Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

Role: lead

NCT05582590Phase 1Not Yet Recruiting

Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers

Role: lead

NCT04284228Phase 1Unknown

Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT

Role: lead

All 3 trials loaded